trending Market Intelligence /marketintelligence/en/news-insights/trending/j2KCzY3Iw5Wesq3aJDJO2w2 content esgSubNav
In This List

US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


US FDA accepts Samsung Bioepis' application for Herceptin biosimilar

The U.S. Food and Drug Administration accepted Samsung Bioepis Co. Ltd.'s biologics license application for its biosimilar version of Roche Holding AG's breast cancer drug Herceptin.

If approved, SB3 will be commercialized in the U.S. by Merck & Co. Inc.

SB3 is Samsung Bioepis' first oncology biosimilar candidate submitted for regulatory approval in the U.S.